Results 131 to 140 of about 53,202 (260)
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]
, 2010 Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10736-10742, November 2026.ABSTRACT Aims To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial. Materials and Methods Continuous glucose monitoring (CGM) data were collected during a 12‐week extension phase after the ADJUST‐T1D trial.
Eslam Montaser +6 more
wiley +1 more source
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT Background As poor sleep negatively impacts on adiposity, there is interest in examining whether improving sleep can improve adiposity markers. We reviewed studies aimed at improving sleep using (1) cognitive behavioral therapy for insomnia (CBT‐I) and/or sleep hygiene and (2) sleep extension on adiposity markers, dietary intake, and physical ...
Samiul A. Mostafa +7 more
wiley +1 more source
Cardiovascular Effects of GLP-1RA in Patients with Type 2 Diabetes [PDF]
The rising prevalence of type 2 diabetes mellitus (T2DM) in the US has led to an increased risk of cardiovascular disease (CVD) among affected individuals.
Legner, Courtney +2 more
core +1 more source
GLP Online Fachforum – Erster Entwurf der GLP Bundesstelle zur Neufassung der ChemVwV-GLP
Der Vortrag stellt die ChemVwV-GLP und Gründe für die Aktualisierung vor, beschreibt die Beteiligung der Bundesländer, gibt eine Kurzvorstellung zu wesentlichen Änderungen des ChemVwV-GLP Entwurfs der GLP-Bundesstelle und stellt das heutige Programm mit ...
Strüh, Christian
core
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
Exclusion of Older Adults from Obesity Treatment Pivotal Trials of GLP-1RAs and GIP/GLP-1RAs
Journal of General Internal MedicineAlissa S. Chen +4 more
openaire +2 more sources
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION Whether glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) activation lowers Alzheimer's disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain‐cortex cis‐acting expression quantitative trait loci (cis‐eQTLs) for GLP‐1R as instruments, we performed cis ...
Li Jiang +17 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1092-1100, October 2026.Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez +6 more
wiley +1 more source